Belinda studie
Titel: Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial
≥ 1ste lijn
NB Studie is gesloten sinds 8 januari 2021
- Protocol (kwadraet)
- Inclusie criteria
- Patienteninformatie (kwadraet)
- CRS flowchart (kwadraet)
Studie coordinator: Roberto Liu